Simplify Asset Management Inc. Acquires 76,440 Shares of Fulcrum Therapeutics, Inc. $FULC

Simplify Asset Management Inc. increased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 91.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 159,674 shares of the company’s stock after purchasing an additional 76,440 shares during the period. Simplify Asset Management Inc.’s holdings in Fulcrum Therapeutics were worth $1,806,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Fulcrum Therapeutics in the fourth quarter worth $30,000. Quarry LP bought a new stake in shares of Fulcrum Therapeutics in the third quarter worth $35,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Fulcrum Therapeutics in the fourth quarter worth $100,000. Russell Investments Group Ltd. grew its stake in shares of Fulcrum Therapeutics by 4,209.3% in the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after purchasing an additional 9,092 shares during the last quarter. Finally, Assetmark Inc. bought a new stake in shares of Fulcrum Therapeutics in the third quarter worth $88,000. Institutional investors own 89.83% of the company’s stock.

Wall Street Analysts Forecast Growth

FULC has been the topic of several analyst reports. Truist Financial set a $17.00 price objective on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. Leerink Partners reaffirmed an “outperform” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. Wall Street Zen raised shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, April 21st. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Fulcrum Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Fulcrum Therapeutics Price Performance

FULC stock opened at $6.57 on Monday. The stock has a market capitalization of $437.76 million, a PE ratio of -5.71 and a beta of 3.02. The company’s 50-day moving average is $7.31 and its 200-day moving average is $9.27. Fulcrum Therapeutics, Inc. has a 1 year low of $5.88 and a 1 year high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. On average, analysts anticipate that Fulcrum Therapeutics, Inc. will post -1.16 earnings per share for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.